CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,955,041 | +129.3% | 435,610 | +38.9% | 0.03% | +65.0% |
| Q2 2023 | $5,651,036 | -18.9% | 313,598 | -27.7% | 0.02% | -80.8% |
| Q1 2023 | $6,965,142 | -6.2% | 433,695 | +6.9% | 0.10% | -23.0% |
| Q4 2022 | $7,421,730 | +51.2% | 405,559 | +62.2% | 0.14% | +43.6% |
| Q3 2022 | $4,910,000 | +70.8% | 250,014 | +62.2% | 0.09% | +19.0% |
| Q2 2022 | $2,874,000 | -28.7% | 154,092 | -16.0% | 0.08% | -26.9% |
| Q1 2022 | $4,029,000 | +61.9% | 183,543 | +109.5% | 0.11% | +40.3% |
| Q4 2021 | $2,489,000 | +1355.6% | 87,608 | +624.0% | 0.08% | +600.0% |
| Q4 2020 | $171,000 | – | 12,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |